Stealth BioTherapeutics' filing for rare disease drug elamipretide has been turned down by the FDA, although the company says the US regulator has given it a "path forward" for the programme.
Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Michael Logan is an experienced writer, producer, and editorial leader. As a journalist, he ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback